ArticlePharmaceutical nanotechnology2026
Calcium Nanoliposome Improves Glycemic Control in a Mouse Diabetes Mellitus Model.
Article in Pharmaceutical nanotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
introductionIntracellular calcium in pancreatic beta cells plays a crucial role in insulin synthesis and secretion. Diabetes impairs this calcium-mediated action, necessitating an effective delivery system such as liposomes to facilitate calcium uptake.
methodsCalcium lactate nanoliposomes (6.25 mg/mL) were prepared via the thin-film hydration method using lecithin and cholesterol as bilayer lipids. Their glucose-lowering efficacy was tested in hyperglycemic mice induced by oral glucose (1 g/kg) and intraperitoneal streptozotocin (45 mg/kg). Pancreatic calcium levels were measured using X-ray fluorescence to verify calcium delivery to beta cells.
resultsThe nanoliposomes exhibited a diameter of 172.1 nm, zeta potential of -53.45 mV, polydispersity index of 0.203, and pH 7.2. Entrapment efficiency was 93.42%, with stable pH and particle size over six cycles. Treatment with calcium nanoliposomes significantly reduced blood glucose levels in both diabetic and glucose-loaded mice. Pancreatic calcium concentrations were higher in animals receiving calcium nanoliposomes compared to controls. DISCUSSION: Calcium nanoliposomes induced a significant glucose reduction relative to controls (empty liposomes, distilled water, and calcium in distilled water). Encapsulation within liposomal vesicles enhanced calcium delivery to pancreatic beta cells, increasing intracellular calcium and stimulating insulin production and release. This was corroborated by elevated pancreatic calcium levels observed via X-ray fluorescence in treated animals.
conclusionCalcium nanoliposomes effectively improve glycemic control in diabetic and glucosechallenged animal models by enhancing calcium delivery to pancreatic beta cells.
Indexed as
Identifiers
40619659What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.